Vasculitis associated with all trans retinoic acid (ATRA) in a case with acute promyelocytic leukemia.
All trans retinoic acid is the drug of choice in the treatment of acute promyelocytic leukemia. But this drug has some side effects, some of which may be life-threatening. Retinoic acid syndrome is the most frequent and dangerous side effect of this differentiation inducing agent. Other side effects include Sweet's syndrome, vasculitis, hypercalcemia, bone marrow necrosis and fibrosis, thromboembolic events, erythema nodosum, granulomatous proliferation and some pulmonary complications. Here, we report vasculitis in a case with APL treated with ATRA and review the literature.
Paydas
Semra
S
Department of Oncology, Cukurova University, Faculty of Medicine, Cukurova University Adana, Turkey. sepay@cu.edu.tr
Yavuz
Sinan
S
Disel
Umut
U
Sahin
Berksoy
B
Canbolat
Tugba
T
Tuncer
Ilhan
I
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005334:Fever / Q000139:chemically induced; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D012074:Remission Induction; D014212:Tretinoin / Q000008:administration & dosage / Q000009:adverse effects*; D014657:Vasculitis / Q000139:chemically induced* / Q000188:drug therapy
D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D014212:Tretinoin; D008775:Methylprednisolone